In a surprising twist of medical fate, the herpes virus—long known as an annoying, recurring rash-maker—may soon be your body’s best line of defense against advanced skin cancer.
A genetically modified version of herpes simplex virus type 1, known as RP1, is being hailed as a potential game-changer in the fight against melanoma, one of the deadliest forms of skin cancer. In a recent clinical trial involving 140 people with hard-to-treat, advanced melanoma, about a third of participants who received RP1 in combination with the immunotherapy drug nivolumab experienced tumor shrinkage. Even more remarkably, half of those responders saw their tumors vanish entirely.
Related: Herpes and STDs in the Middle East
RP1 doesn’t just rely on brute viral force. It’s been engineered to selectively infect and kill cancer cells while leaving healthy ones intact. Once inside the tumor, RP1 replicates and bursts cancer cells open, triggering the immune system to recognize and destroy the remaining malignancies. Combined with nivolumab—a checkpoint inhibitor that helps immune cells stay active—the results have been promising enough to attract attention from the U.S. Food and Drug Administration (FDA).
According to Dr. Gino Kim In, the oncologist overseeing the RP1 study, the FDA could greenlight the therapy as soon as the end of this month, potentially making RP1 the second virus-based cancer therapy ever approved in the US, after Amgen’s T-VEC (also based on herpes).
A larger, confirmatory trial involving 400 patients is still underway. But the urgency of treating late-stage cancers, and the strength of the early data, could fast-track approval.
This isn’t the first time viruses have been enlisted to fight disease—they’ve been modified to deliver gene therapies, kill antibiotic-resistant bacteria, and now, to train the immune system like a microbial bootcamp. What makes RP1 stand out is its double action: kill cancer cells directly and activate the immune system for the long haul.
Related: half of all medical cannabis (CBD and THC) not labelled right
So, can herpes kill cancer? Not the kind you catch on a bad date. But a lab-modified version of the virus might just save lives, turning a once-feared pathogen into a new kind of precision weapon in oncology.
We’re watching closely for the FDA’s verdict. Because if RP1 gets the green light, it won’t just be a victory for virology—it’ll mark a new era in living cancer drugs.
